Welcome to our dedicated page for Editas Medicine SEC filings (Ticker: EDIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Editas Medicine, Inc. (Nasdaq: EDIT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a clinical-stage gene editing company focused on in vivo CRISPR/Cas12a and CRISPR/Cas9 medicines, Editas uses current reports on Form 8-K and other periodic filings to communicate material events, program updates, collaborations, and financial results to investors.
Through its 8-K filings, Editas Medicine furnishes press releases announcing quarterly financial results, cash runway expectations, and business highlights. These documents describe research and development expenses, collaboration and other research revenues, restructuring and impairment charges, and the company’s view of its ability to fund operating expenses and capital expenditure requirements over a multi-year period. They also outline key risk considerations and refer readers to the company’s Annual Report on Form 10-K and subsequent filings for detailed risk factors.
Filings also summarize important scientific and pipeline milestones. For example, Editas has used 8-K reports to describe the nomination of EDIT-401 as its lead in vivo development candidate for hyperlipidemia, preclinical proof-of-concept data demonstrating approximately 90% LDL-C reduction in non-human primates and mice, and the therapeutic strategy of using CRISPR/Cas9 with dual guide RNAs and lipid nanoparticle delivery to upregulate LDLR. Other filings discuss in vivo proof-of-concept data for EDIT-401 presented at major gene and cell therapy conferences.
Investors can review these SEC filings to understand how Editas Medicine reports the status of its in vivo HSC program for sickle cell disease and beta thalassemia, its collaboration with Bristol Myers Squibb on T cell medicines, and payments under its license agreement with Vertex Pharmaceuticals. On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key sections related to EDIT-401, cash runway, collaborations, and program changes, and make it easier to interpret complex technical and financial disclosures without reading every line of each document.
Editas Medicine CEO O'Neill Gilmore Neil reported an automatic tax-related share sale. On March 3, 2026, he sold 5,394 shares of Editas Medicine common stock in open-market transactions at a weighted average price of $2.0197 per share. The footnotes explain the sale was executed under a durable automatic sales instruction plan adopted on April 13, 2022 to cover tax withholding on restricted stock units that vested on March 2, 2026, and did not represent a discretionary trade. Following this transaction, he held 263,693 shares of common stock directly.
Editas Medicine, Inc. Senior Vice President and Chief Financial Officer Amy Parison reported an open-market sale of 474 shares of common stock at a weighted average price of $2.02 per share on March 3, 2026. According to the disclosure, the sale was executed under a durable automatic sales instruction plan adopted on July 7, 2022 and was made solely to cover tax withholding obligations arising from restricted stock units that vested on March 2, 2026, rather than as a discretionary trade. After this transaction, Parison directly owned 15,434 shares of Editas Medicine common stock.
Editas Medicine, Inc. executive Linda Burkly, EVP and Chief Scientific Officer, reported an open-market sale of 749 shares of common stock at a weighted average price of $2.0196 per share. After this transaction, she held 68,028 shares of Editas Medicine common stock.
According to the disclosure, the sale was carried out under a durable automatic sales instruction plan adopted on July 3, 2023 and was made to cover tax withholding obligations from restricted stock units that vested on March 2, 2026. The filing states that this was not a discretionary trade by the reporting person.
Gilmore O'Neill submitted a Form 144 reporting proposed and recent transactions in Common Stock. The filing lists 11,294 shares tied to a Restricted Stock Unit Vesting dated 03/02/2026 and a prior sale of 5,603 shares on 12/03/2025 for 12063.82.
Editas Medicine reported Q3 2025 results with collaboration revenue of $7.5 million driven by a BMS milestone. Operating expenses fell sharply after the 2024 program discontinuation, with R&D at $19.8 million and G&A at $12.3 million. The quarter’s operating loss was $24.5 million and net loss was $25.1 million, or $0.28 per share.
Cash and cash equivalents were $165.6 million, and management states existing cash is expected to fund operations into the third quarter of 2027. Year to date, the company recorded $66.9 million of restructuring and impairment charges tied to the wind-down of its ex vivo program, while interest expense reflects its sale of certain future Vertex-related payments. Common shares outstanding were 97,618,660 as of October 31, 2025.
The company raised $25.8 million net through its at-the-market equity program in the first nine months of 2025 and had $123.6 million of capacity remaining as of September 30, 2025. Authorized common stock increased to 390,000,000 shares. Editas is prioritizing in vivo programs, including EDIT-401 for LDL-C reduction.
Editas Medicine reported that it furnished a press release announcing financial results for the fiscal quarter ended September 30, 2025, along with other business highlights.
The press release was provided as Exhibit 99.1 and designated as furnished, not filed. The company’s common stock trades on Nasdaq under the symbol EDIT.
Editas Medicine, Inc. filed a report describing new preclinical data for EDIT-401, an experimental one-time gene-editing therapy designed to significantly reduce LDL-cholesterol by increasing LDL receptor levels. At a major gene and cell therapy congress, the company reported that in non-human primates a single dose of EDIT-401 led to LDL-C reductions equal to or exceeding 90% within 48 hours. Similar LDL-C reductions of at least 90% were also seen in mice with high baseline LDL-C and reduced LDL receptor function, with effects maintained over a three-month study. The therapy uses a CRISPR/Cas9 nuclease with dual guide RNAs delivered via lipid nanoparticles to disrupt negative regulatory elements in the 3’ UTR, which Editas says increased LDL receptor protein in primate liver by at least six-fold while requiring only moderate functional editing of LDLR alleles.
Linda C. Burkly, Executive Vice President and Chief Scientific Officer of Editas Medicine, reported a sale of 710 shares of the issuer's common stock on 09/03/2025 at a price of $2.5961 per share. The filing states the sale was effected under a durable automatic sales instruction plan adopted July 3, 2023, to satisfy tax withholding triggered by restricted stock units that vested on 09/02/2025, and the sale was not a discretionary trade. Following the transaction Burkly beneficially owns 69,490 shares, which includes 5,802 shares acquired under the company Employee Stock Purchase Plan.
Editas Medicine insider sale disclosed on Form 4: Amy Parison, SVP and Chief Financial Officer, reported a transaction dated 09/03/2025 showing the disposition of 458 shares of Editas Medicine common stock at a price of $2.5961 per share. After the sale, Ms. Parison beneficially owned 16,369 shares, held directly. The filing states the sale was effected under a durable automatic sales instruction plan adopted July 7, 2022, to satisfy tax withholding obligations tied to the vesting of restricted stock units on 09/02/2025, and that the sale was not a discretionary trade by the reporting person.
Editas Medicine director and CEO Gilmore O'Neill sold 5,592 shares of Editas Medicine (EDIT) on 09/03/2025 at $2.5961 per share under a pre-existing Rule 10b5-1 automatic sales plan. The filing states the sale was to satisfy tax withholding obligations arising from restricted stock units that vested on 09/02/2025 and was not a discretionary trade. After the transaction the reporting person beneficially owned 274,690 shares.